Super-enhancer-based identification of a BATF3/IL-2R-module reveals vulnerabilities in anaplastic large cell lymphoma

Logo poskytovatele

Varování

Publikace nespadá pod Filozofickou fakultu, ale pod Středoevropský technologický institut. Oficiální stránka publikace je na webu muni.cz.
Autoři

LIANG H.C. COSTANZA M. PRUTSCH N. ZIMMERMAN M.W. GURNHOFER E. MONTES-MOJARRO I.A. ABRAHAM B.J. PROKOPH N. STOIBER S. TANGERMANN S. LOBELLO Cosimo OPPELT Jan ANAGNOSTOPOULOS I. HIELSCHER T. PERVEZ S. KLAPPER W. ZAMMARCHI F. SILVA D.A. GARCIA K.C. BAKER D. JANZ M. SCHLEUSSNER N. FEND F. POSPÍŠILOVÁ Šárka JANIKOVA A. WALLWITZ J. STOIBER D. SIMONITSCH-KLUPP I. CERRONI L. PILERI S. DE LEVAL L. SIBON D. FATACCIOLI V. GAULARD P. ASSAF C. KNORR F. DAMM-WELK C. WOESSMANN W. TURNER Suzanne Dawn LOOK A.T. MATHAS S. KENNER L. MERKEL O.

Rok publikování 2021
Druh Článek v odborném periodiku
Časopis / Zdroj Nature Communications
Fakulta / Pracoviště MU

Středoevropský technologický institut

Citace
www https://www.nature.com/articles/s41467-021-25379-9
Doi http://dx.doi.org/10.1038/s41467-021-25379-9
Klíčová slova HODGKIN LYMPHOMANPM-ALKCD30 PROMOTERKINASEANTIBODYTUMORTRANSLOCATIONSINHIBITIONDIAGNOSISIDENTITY
Popis Anaplastic large cell lymphoma (ALCL), an aggressive CD30-positive T-cell lymphoma, comprises systemic anaplastic lymphoma kinase (ALK)-positive, and ALK-negative, primary cutaneous and breast implant-associated ALCL. Prognosis of some ALCL subgroups is still unsatisfactory, and already in second line effective treatment options are lacking. To identify genes defining ALCL cell state and dependencies, we here characterize super-enhancer regions by genome-wide H3K27ac ChIP-seq. In addition to known ALCL key regulators, the AP-1-member BATF3 and IL-2 receptor (IL2R)-components are among the top hits. Specific and high-level IL2R expression in ALCL correlates with BATF3 expression. Confirming a regulatory link, IL-2R-expression decreases following BATF3 knockout, and BATF3 is recruited to IL2R regulatory regions. Functionally, IL-2, IL-15 and Neo-2/15, a hyper-stable IL-2/IL-15 mimic, accelerate ALCL growth and activate STAT1, STAT5 and ERK1/2. In line, strong IL-2R alpha-expression in ALCL patients is linked to more aggressive clinical presentation. Finally, an IL-2R alpha-targeting antibody-drug conjugate efficiently kills ALCL cells in vitro and in vivo. Our results highlight the importance of the BATF3/IL-2R-module for ALCL biology and identify IL-2R alpha-targeting as a promising treatment strategy for ALCL.
Související projekty:

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.